The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - PharmaEssentia
Leadership - PharmaEssentia
Stock and Other Ownership Interests - PharmaEssentia
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
 
Lucia Masarova
No Relationships to Disclose
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; MorphoSys; Novartis; PharmaEssentia; Roche; Sierra Oncology
Research Funding - Abbvie; Bristol-Myers Squibb; CTI; Geron; Incyte; Kartos Therapeutics; PharmaEssentia
 
Albert Qin
No Relationships to Disclose
 
Weichung Shih
Consulting or Advisory Role - PharmaEssentia
 
Toshiaki Sato
Employment - PharmaEssentia
Leadership - PharmaEssentia
 
Raymond Urbanski
Employment - PharmaEssentia
Leadership - PharmaEssentia
Stock and Other Ownership Interests - PharmaEssentia
 
Oleh Zagrijtschuk
Consulting or Advisory Role - PharmaEssentia
 
Craig Zimmerman
Employment - PharmaEssentia
Stock and Other Ownership Interests - PharmaEssentia